COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB

被引：0
|
作者：
Minami, M. [1 ]
Miyamoto, T. [1 ]
Akashi, K. [1 ]
机构：
[1] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1816
引用
收藏
页码：728 / 728
页数：1
相关论文
共 50 条
  • [21] In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Khorashad, Jamshid S.
    Milojkovic, Dragana
    Mehta, Puja
    Anand, Mona
    Ghorashian, Sara
    Reid, Alistair G.
    De Melo, Valeria
    Babb, Anna
    de lavallade, Hugues
    Olavarria, Eduardo
    Marin, David
    Goldman, John M.
    Apperley, Jane F.
    Kaeda, Jaspal S.
    BLOOD, 2008, 111 (04) : 2378 - 2381
  • [22] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
    Park, J.
    Kwon, H.
    Shin, M.
    Shin, S.
    Lee, J. Y.
    VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
  • [23] Nilotinib leads to sustained responses in CML patients with residual disease on imatinib
    Fuerst, Mark L.
    FORMULARY, 2013, 48 (07) : 237 - 237
  • [24] A cost-utility analysis of nilotinib for CML patients who have become resistant to imatinib
    Jewitt, K.
    Pilgrim, H.
    Ward, S.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 38 - 38
  • [25] Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib for Patients with Chronic Myeloid Leukemia
    Miura, Masatomo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2015, 38 (05) : 645 - 654
  • [26] Compassionate use experience with dasatinib therapy in patients after imatinib and/or nilotinib failure
    Gunawardena, Bettina A.
    Schlief, Sarah
    Dempke, Wolfram
    Wnterhalter, Bernd
    BLOOD, 2007, 110 (11) : 212B - 212B
  • [27] Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil
    Quissak, C.
    Litalien, G.
    Alves, M. R.
    VALUE IN HEALTH, 2008, 11 (03) : A64 - A64
  • [28] Long Term Outcomes Of Pulmonary Arterial Hypertension In Patients Treated With Dasatinib
    Weatherald, J.
    Chaumais, M. -C.
    Savale, L.
    Jais, X.
    Seferian, A.
    Sitbon, O.
    Simonneau, G.
    Guignabert, C.
    Humbert, M.
    Montani, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [29] Incidence of grade 3/4 adverse events in imatinib resistant/intolerant chronic phase CML (CP-CML): A comparison of nilotinib and dasatinib
    Carpiuc, K. T.
    Stephens, J. M.
    Liou, S. Y.
    Botteman, M. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [30] Comparison of Effects of Imatinib and Nilotinib in a Rodent Model of Pulmonary Arterial Hypertension
    Duggan, N.
    Bonneau, O.
    Hussey, M.
    Quinn, D. A.
    Manley, P.
    Walker, C.
    Westwick, J.
    Thomas, M. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
12345